The American Cancer Society's updated colorectal cancer screening recommendations, incorporating blood-based tumor DNA detection (Shield) and multi-target stool assays (updated Cologuard and ColoSense), mark a strategic pivot toward accessibility. Yet this expansion, driven by rising incidence in adults under 50, overlooks critical evidentiary weaknesses and systemic barriers that peer-reviewed data highlight. The Healthline report summarizes ACS positions but fails to scrutinize the underlying studies: Shield's FDA approval rested on the ECLIPSE observational cohort (n=7,861 average-risk adults), lacking randomization and showing only 83% sensitivity for cancer with moderate precancer detection, per a 2024 NEJM publication with industry funding from Guardant Health. In contrast, colonoscopy efficacy derives from large RCTs like the Nordic-European Initiative on Colorectal Cancer (NordICC, n=84,585), demonstrating 18% relative mortality reduction at 10 years. Stool tests occupy an intermediate space, with Cologuard's pivotal study (n=9,989) observational in design and prone to specificity issues around 87%, inflating follow-up colonoscopies. Original coverage neglects how these alternatives address real disparities—rural and low-income populations face 20-30% lower colonoscopy uptake due to logistics and fear—but without addressing adherence to the mandated 6-month diagnostic colonoscopy post-positive non-invasive result, which observational data show drops below 50% in underserved groups. Cost-effectiveness analyses from USPSTF-linked models further reveal blood tests may increase overall spending by 15-25% via cascades of testing, absent head-to-head RCTs. Synthesizing ACS reports with NordICC and ECLIPSE underscores that while any completed screen outperforms none, prioritizing volume over validated performance risks widening outcome gaps rather than closing them.